Lamotrigine: how effective is it as add-on therapy in Bulgarian patients with drug-resistant epilepsy

Ekaterina Ivanova Viteva; Zahari Ivanov Zahariev

doi:10.30574/gscbps.2019.8.3.0164

Authors

Ekaterina Ivanova Viteva Department of Neurology, Medical University – Plovdiv, Bulgaria UMHAT St. George, Plovdiv, Bulgaria.
Zahari Ivanov Zahariev Department of Neurology, Medical University – Plovdiv, Bulgaria UMHAT St. George, Plovdiv, Bulgaria.

DOI:

https://doi.org/10.30574/gscbps.2019.8.3.0164

Keywords:

Lamotrigine, Epilepsy, Efficacy, Tolerability, Adverse events

Abstract

The study purpose was to perform an open, prospective study on various aspects of Lamotrigine (LTG) effectiveness in Bulgarian patients with drug-resistant epilepsy. The study was performed with the participation of patients with epilepsy who attended the Clinic of Neurology at the University Hospital in Plovdiv, Bulgaria. The patients completed diaries about seizure frequency, severity, and adverse events. There were regular documented visits at 3 or 6 months during the first year of treatment with LTG and at 6 months afterwards, with dynamic assessment of seizure frequency, severity, adverse events, and EEG recordings. LTG was applied as add-on treatment in 73 patients (47 males, mean age 36 years). There was a relatively mild and stable dynamic improvement of seizure severity, a satisfactory seizure frequency reduction in 39.7% of participants, a stable mean seizure frequency reduction (43-59%) from the 6^th to the 36^th month of treatment and a stable responder rate (55.7-59.4%) during the same period. There were adverse events (dizziness/vertigo, generalized edema, irritability, aggressiveness, speech disturbances, visual hallucinations, sleepiness, insomnia, headache, diplopia, nystagmus, impaired balance, muscle cramps, gastrointestinal discomfort, generalized rash, fatigue, nausea) in 12.3% of patients. In conclusion, LTG treatment is associated with: a low and stable improvement of seizure severity, a good and stable improvement of seizure frequency, a possible worsening of seizure control, a good safety and tolerability.

Metrics

Metrics Loading ...

References

Dion MH, Novotny E, Carmant L, Cossette P and Nguyen DK. (2007). Lamotrigine therapy of epilepsy with Angelman’s syndrome. Epilepsia, 48(3), 593-596.

Donaldson J, Glauser T and Olberding L. (1997) Lamotrigine adjunctive therapy in childhood epileptic encephalopathy (The Lennox-Gastaut Syndrome). Epilepsia, 38(1), 68-73.

Steinhoff B, Ueberall M, Siemes H, Kurlemann G, Schmitz B, Bergmann L and The LAM-SAFE Study Group. (2005). The LAM-SAFE Study: Lamotrigine versus carbamazepine or valproic acid in newly diagnosed focal and generalised epilepsies in adolescents and adults. Seizure, 14, 597-605.

Steiner TJ, Dellaportas CI, Findley TL, Gross M, Gibberd FB, Perkin GD, Park ID and Abbott R.(1999). Lamotrigine Monotherapy in Newly Diagnosed Untreated Epilepsy: A Double-Blind Comparison with Phenytoin. Epilepsia, 40(5), 601-607.

Jozwiak S and Terczynski A. (2000). Open study evaluating lamotrigine efficacy and safety in add-on treatment and consecutive monotherapy in patients with carbamazepine- or valproate-resistant epilepsy. Seizure, 9, 486-492.

Stables JP, Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P and Perucca E. (1995). Progress report on new antiepileptic drugs. A summary of the second Eilat Conference. Conference review. Epilepsy Res, 22, 235-246.

Smith D, Baker G, Davies G, Dewey M and Chadwick DW. (1993). Outcomes of add-on treatment with lamotrigine in partial epilepsy. Epilepsia, 34(2), 312-322.

Matsuo F, Bergen D, Faught E, Messenheimer JA, Dren AT, Rudd GD and Lineberry CG. (1993). Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. U.S. Lamotrigine protocol 0.5 clinical trial group. Neurology, 43(11), 2284-2291.

Messenheimer J, Ramsay RE, Willmore LJ, Leroy RF, Zielinski JJ, Mattson R, Pellock JM, Velakas AM, Womble G and Risner M. (1994). Lamotrigine therapy for partial seizures: a multicenter, placebo-controlled, double-blind, cross-over trial. Epilepsia, 35(1), 113-121.

De Romanis F and Sopranzi N. (1995) .Lamotrigine: first experience in Italy. Clin Ter, 146(3), 203-209.

Beran RG, Bercivic SF, Dunagan FM, Vajda FJ, Black AB and Mackenzie R. (1999). Double-blind, placebo-controlled cross-over study of lamotrigine in treatment-resistant generalized epilepsy. Epilepsia, 40, 1439-1445.

Sander JW, Patsalos PN and Oxley JR. (1990). A randomized, double-blind, placebo-controlled add-on trial of lamotrigine in patients with severe epilepsy. Epilepsy Res, 6, 221-226.

Timmings PL and Richens A. (1992). Lamotrigine as an add-on drug in the management of Lennox-Gastaut syndrome. Eur Neurol, 32, 305-307.

Schlumberger E, Chavez F, Palacios L, Rey E, Pajot N and Dulac O. (1994). Lamotrigine in treatment of 120 children with epilepsy. Epilepsia, 35, 359-367.

Uvebrant P and Bauziene R. (1994). Intractable epilepsy in children. The efficacy of lamotrigine treatment, including non-seizure related benefits. Neuropediatrics, 25, 284-289.

Buchanan N. (1995). Lamotrigine: clinical experience in 93 patients with epilepsy. Acta Neurol Scand, 92, 28-32.

Cocito L, Maffini M and Loeb C. (1994). Long-term observations on the clinical use of lamotrigine as add-on drug in patients with epilepsy. Epilepsy Res, 19, 123-127.

Alegre M, Iriarte J, Schlumberger E, Urrestarazu E, Lázaro D and Viteri C. (2002). Lamotrigine in the adult-onset epilepsy: efficacy and long-term safety. Neurologia, 17(3), 136-42.

Arzimanoglou A, Kulak I, Bidaut-Mazel C and Baldy-Moulinier M. (2001). Optimal use of lamotrigine in clinical practice: results of an open multicenter trial in refractory epilepsy]. Rev Neurol (Paris), 157(5), 525-536.

Mauri-Llerda JA, Tejero C, Espada F, Iñiguez C and Morales F. (2001). Lamotrigine in refractory partial and general epilepsies. Rev Neurol, 32(1), 42-45.

Pimentel J, Guimarães ML, Lima L, Leitão O and Sampaio MJ. (1999). Lamotrigine as add-on therapy in treatment-resistant epilepsy. Portuguese Lamotrigine as Add-on Therapy in Treatment-resistant Epilepsy Study Group. J Int Med Res, 27(3), 148-157.

Crawford P, Brown S, M. Kerr and Parke Davis Clinical Trials Group. (2001). A randomized open-label study of gabapentin and lamotrigine in adults with learning disability and resistant epilepsy. Seizure, 10, 107-115.

Kuzmanova R. (2015). Adverse events from treatment with antiepileptic drugs – importance for the therapeutic approach and impact on the quality of life of patients with epilepsy. Ph.D. thesis, Medical University - Sofia, Bulgaria.

Kalpachki R and Shotekov P. (2002). Clinical experience in the treatment of epilepsy with Lamotrigine. Bulgarian Neurology, 2(1), 21-24.

Rasheva M, Milanova M, Radeva M and Atanasova D. (2004). Assessment of the newer generation antiepileptic drugs as add-on therapy in refractory partial epilepsies. Bulgarian Neurology, 4(4), 173-178.

Brodie MJ, Richens A and Yuen AW. (1995). Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Lancet, 345(8948), 476-479.

Rowan AJ, Ramsay RE, Collins JF, Pryor F, Boardman KD, Uthman BM, Spitz M, Frederick T, Towne A, Carter GS, Marks W, Felicetta J, Tomyanovich ML and VA Cooperative Study 428 Group. (2005).New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. Neurology, 64, 1868-1873.

Kwan P, Brodie MJ, Kälviäinen R, Yurkewicz L, Weaver J and Knapp LE. (2011). Efficacy and safety of pregabalin versus lamotrigine in patients with newly diagnosed partial seizures: a phase 3, double-blind, randomised, parallel-group trial. Lancet Neurol, 10(10), 881-90.

Valencia С, Piňol-Ripoll G, Khurana D, Hardison H, Kothare S, Melvin J, Marks HG and Legido A. (2009). Efficacy and safety of lamotrigine monotherapy in children and adolescents with epilepsy. European Journal of Paediatric Neurology, 13, 141-145.

Duchowny M, Gilman J, Messenheimer J, Womble G and Risner M. (2002). Long-term tolerability and efficacy of lamotrigine in pediatric patients with epilepsy. J Child Neurol, 17, 278-285.

Barron TF, Hunt SL, Hoban TF and Price ML. (2000). Lamotrigine monotherapy in children. Pediatr Neurol, 23, 160-163.

Dooley J, Camfield P, Gordon K, Camfield C, Wirrell Z and Smith E. (1996). Lamotrigine-induced rash in children. Neurology, 46, 240-242.

Guberman AH, Besag FM, Brodie MJ, Dooley JM, Duchowny MS, Pellock JM, Richens A, Stern RS and Trevathan E. (1999). Lamotrigine associated rash: risk/benefit considerations in adults and children. Epilepsia, 40, 985-991.

Allain H, Schuck S, Nachit-Ouinekh F, Plouin P, Brunon AM, Boulliat J, Mercier F, Slama A, Baulac M, El Hasnaoui A. (2007). Improvement in quality of life after initiation of lamotrigine therapy in patients with epilepsy in a naturalistic treatment setting. Seizure, 16, 173-184.

Reunanen M, Dam M and Yuen A. (1996). A randomized open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Res, 23, 149-155.

Besag F, Wallace S, Dulac O, Alving J, Spencer S and Hosking G. (1995). Lamotrigine for he treatment of epilepsy in childhood. The Journal of pediatrics, 127(6), 991-997.

Zubcevic S, Cengic A, Catibusic F and Uzicanin S. (2008). Use of lamotrigine in medically intractable epilepsies in children. Med Arh, 62(3), 162-164.

Veroniki AA, Cogo E, Rios P, Straus SE, Finkelstein Y, Kealey R, Reynen E, Soobiah C, Thavorn K, Hutton B, Hemmelgarn BR, Yazdi F, D'Souza J, MacDonald H and Tricco AC. (2017). Comparative safety of anti-epileptic drugs during pregnancy: a systematic review and network meta-analysis of congenital malformations and prenatal outcomes. BMC Med, 5, 15(1), 95.